Company news
Revive Therapeutics Ltd. (CSE:RVV) news
Revive Therapeutics Ltd. news releases on 6ix. Latest, Sep 15, 2026: Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical…
Press releases & updates
Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases
September 15, 2026
Revive Therapeutics Announces Proposed Shares for Debt Settlement
August 19, 2026
Revive Therapeutics Reports Grant of Options
August 14, 2026
Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study
August 12, 2026
Revive Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement
July 15, 2026
Revive Therapeutics Announces Proposed Private Placement
June 26, 2026
Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures
May 20, 2026
Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study
December 15, 2025
Revive Therapeutics Announces Closing of Second Tranche of Private Placement
September 19, 2025
Revive Therapeutics Announces Extension of Proposed Private Placement
September 5, 2025
Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement
August 11, 2025
Revive Therapeutics Announces Proposed Private Placement and Debt Settlement
July 29, 2025
Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study
July 8, 2025
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
June 26, 2025
Revive Therapeutics Advances with Next-Generation Bucillamine Development
June 4, 2025
Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
May 12, 2025
Revive Therapeutics Announces Proposed Shares for Debt Transaction
April 21, 2025
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
April 10, 2025
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
April 1, 2025
Revive Therapeutics Announces Results of Annual Shareholder Meeting
March 19, 2025
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
March 3, 2025
Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
February 3, 2025
Revive Therapeutics Prices and Files Final Prospectus for Equity Financing
December 5, 2014
IIROC Trade Halt - Mercury Capital II Limited
July 18, 2013
IIROC Trading Halt - MFF.P
July 18, 2013